DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 1 drugmaker Biogen - 1 Eli Lilly's - 1 — - 1 Lilly - 1 Biogen - 1 Japan's - 1 Chris Viehbacher - 1
Top related locs:
Indianapolis
Top related orgs:
Food and Drug Administration - 1 Drug Administration - 1 Alzheimer's Association - 1 FDA - 1 Club - 1 GE Healthcare - 1 FactSet - 1 Pharmaceutical - 1

Search resuls for: "drugmaker Biogen"


3 mentions found


☆ What Eli Lilly investors can learn from the slow launch of a competitor's drug
  + stars: | 2024-02-15 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +8 min
Club holding Eli Lilly is expecting to get approval for its Alzheimer's treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. The FDA's decision on Lilly's drug, known as donanemab, is expected by the end of March. In the meantime, Eli Lilly's diabetes and obesity drugs, the heart of our investment thesis, should continue to fuel the lion's share of the company's topline growth. About 2,000 patients are currently taking Leqembi, Biogen said Tuesday, up from 800 at the time of the company's third-quarter report in November. LLY YTD mountain Eli Lilly's stock performance so far in 2024.
Persons: Eli Lilly, drugmaker Biogen, Eli Lilly's, —, Lilly, Biogen, Japan's, Chris Viehbacher, Viehbacher, Morgan Stanley, Lilly's, Donanemab, Mounjaro, Jim Cramer, Leqembi, Jim Cramer's, Jim Organizations: Food and Drug Administration, Drug Administration, Alzheimer's Association, FDA, Club, GE Healthcare, FactSet, Pharmaceutical, CNBC Locations: Indianapolis
☆ New Alzheimer's drug slows cognitive decline by 27%, clinical trial finds
  + stars: | 2022-09-28 | by ( Cheryl Teh | ) www.businessinsider.com   time to read: +3 min
A clinical trial of a new Alzheimer's drug from Eisai and Biogen has shown promising results. The large-scale study saw cognitive decline in patients being slowed by 27% over 18 months. The trial involved 1,795 patients with early-stage Alzheimer's. The companies announced the trial's success in a press release on Tuesday, saying their drug — called lecanemab — was observed to have slowed cognitive decline in Alzheimer's patients by 27% over 18 months. The companies noted that around 21% of the patients who received the lecanemab treatment experienced brain swelling that was visible on PET scans.
☆ Experimental Alzheimer's drug shows benefits in phase 3 trial, company says
  + stars: | 2022-09-27 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Berkeley-Lovelace-Jr.Jpg | Berkeley Lovelace Jr. | ) www.nbcnews.com   time to read: +3 min
The Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness. The company said that in a phase 3 clinical trial, the drug, called lecanemab, slowed cognitive decline by 27% after 18 months. The results may offer renewed hope to Alzheimer’s patients after the U.S. drugmaker Biogen’s botched rollout of its drug, Aduhelm, last year. Biogen partnered with Eisai in the commercialization of the new drug, although Eisai led its development and the phase 3 trial. Two similar drugs — from Roche and Eli Lilly — are expected to release late-stage clinical trial results over the next few months.
0 next >>
Total: 3